Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 2634673F

Next Previous
X
Search
Drug Profile

GSK 2634673F

Alternative Names: 18F-FBA-A20FMDV2; GSK263467F

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 04 Mar 2020 Discontinued - Phase-I for Idiopathic pulmonary fibrosis (Diagnosis) in United Kingdom (IV)
  • 28 Sep 2019 Efficacy data from a phase I PETAL trial in Idiopathic pulmonary fibrosis 29th Annual Congress of the European Respiratory Society (ERS-2019)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(Diagnosis) in United Kingdom (IV, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top